Movement Alert｜AstraZeneca Falls 3.18% in Pre-Market Trading, Phase III Clinical Trial Failure Continues to Weigh on Shares

Market Focus06-03 18:35

On June 3, AstraZeneca fell 3.18% in pre-market trading, trading at approximately $171.92/share, with trading volume of $611,900.

The decline reflects continued market repricing following the disclosure that its Alexion rare disease division's CARES Phase III clinical trial evaluating anselamimab for light chain amyloidosis failed to meet its primary endpoint in the overall patient population. While a pre-specified Kappa subgroup demonstrated a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data missed the target, constituting a significant pipeline-level setback.

Within the Pharmacy sector, peers remained largely stable with Eli Lilly up 0.1%, Merck up 0.2%, Johnson & Johnson up 0.07%, Pfizer down 0.16%, and Bristol-Myers Squibb down 0.09%. AstraZeneca's decline significantly exceeds the sector average, indicating the market continues to price in elevated pipeline risk following the clinical readout.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199190393?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199190393","market":"us","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca Falls 3.18% in Pre-Market Trading, Phase III Clinical Trial Failure Continues to Weigh on Shares","media":"Market Focus","content":"<p><p>On June 3, AstraZeneca fell 3.18% in pre-market trading, trading at approximately $171.92/share, with trading volume of $611,900.</p><p>The decline reflects continued market repricing following the disclosure that its Alexion rare disease division's CARES Phase III clinical trial evaluating anselamimab for light chain amyloidosis failed to meet its primary endpoint in the overall patient population. While a pre-specified Kappa subgroup demonstrated a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data missed the target, constituting a significant pipeline-level setback.</p><p>Within the Pharmacy sector, peers remained largely stable with Eli Lilly up 0.1%, Merck up 0.2%, Johnson & Johnson up 0.07%, Pfizer down 0.16%, and Bristol-Myers Squibb down 0.09%. AstraZeneca's decline significantly exceeds the sector average, indicating the market continues to price in elevated pipeline risk following the clinical readout.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca Falls 3.18% in Pre-Market Trading, Phase III Clinical Trial Failure Continues to Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca Falls 3.18% in Pre-Market Trading, Phase III Clinical Trial Failure Continues to Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, AstraZeneca fell 3.18% in pre-market trading, trading at approximately $171.92/share, with trading volume of $611,900.</p><p>The decline reflects continued market repricing following the disclosure that its Alexion rare disease division's CARES Phase III clinical trial evaluating anselamimab for light chain amyloidosis failed to meet its primary endpoint in the overall patient population. While a pre-specified Kappa subgroup demonstrated a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data missed the target, constituting a significant pipeline-level setback.</p><p>Within the Pharmacy sector, peers remained largely stable with Eli Lilly up 0.1%, Merck up 0.2%, Johnson & Johnson up 0.07%, Pfizer down 0.16%, and Bristol-Myers Squibb down 0.09%. AstraZeneca's decline significantly exceeds the sector average, indicating the market continues to price in elevated pipeline risk following the clinical readout.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1199190393","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199190393","pubTimestamp":1780482943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, AstraZeneca fell 3.18% in pre-market trading, trading at approximately $171.92/share, with trading volume of $611,900.The decline reflects continued market repricing following the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"动静快讯|阿斯利康盘前跌3.18%III期临床试验失败继续打压股价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On June 3, AstraZeneca fell 3.18% in pre-market trading, trading at approximately $171.92/share, with trading volume of $611,900.The decline reflects continued market repricing following the disclosure that its Alexion rare disease division's CARES Phase III clinical trial evaluating anselamimab for light chain amyloidosis failed to meet its primary endpoint in the overall patient population. While a pre-specified Kappa subgroup demonstrated a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data missed the target, constituting a significant pipeline-level setback.Within the Pharmacy sector, peers remained largely stable with Eli Lilly up 0.1%, Merck up 0.2%, Johnson & Johnson up 0.07%, Pfizer down 0.16%, and Bristol-Myers Squibb down 0.09%. AstraZeneca's decline significantly exceeds the sector average, indicating the market continues to price in elevated pipeline risk following the clinical readout.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199190393","isCrawlerRequest":true}